Helga K Ising1, Tamar C Kraan2, Judith Rietdijk3, Sara Dragt2, Rianne M C Klaassen4, Nynke Boonstra5, Dorien H Nieman2, Monique Willebrands-Mendrik2, David P G van den Berg6, Don H Linszen2, Lex Wunderink5, Wim Veling7, Filip Smit8, Mark van der Gaag3. 1. Department of Psychosis Research, Parnassia Psychiatric Institute, The Hague, The Netherlands; h.ising@parnassia.nl. 2. Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands; 3. Department of Psychosis Research, Parnassia Psychiatric Institute, The Hague, The Netherlands; Department of Clinical Psychology, VU University and EMGO Institute for Health and Care Research, Amsterdam, The Netherlands; 4. Child and Adolescent Department, University Medical Center, Utrecht, The Netherlands; 5. Department of Research and Education, Friesland Mental Health Services, Leeuwarden, The Netherlands; 6. Department of Psychosis Research, Parnassia Psychiatric Institute, The Hague, The Netherlands; 7. Department of Psychiatry, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands; 8. Department of Clinical Psychology, VU University and EMGO Institute for Health and Care Research, Amsterdam, The Netherlands; Department of Public Mental Health, Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, The Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Previously, we demonstrated that cognitive behavior therapy for ultra-high risk (called CBTuhr) halved the incidence of psychosis over an 18-month period. Follow-up data from the same study are used to evaluate the longer-term effects at 4 years post-baseline. METHOD: The Dutch Early Detection and Intervention Evaluation study was a randomized controlled trial of 196 UHR patients comparing CBTuhr with treatment-as-usual (TAU) for comorbid disorders with TAU only. Of the original 196 patients, 113 consented to a 4-year follow-up (57.7%; CBTuhr = 56 vs TAU = 57). Over the study period, psychosis incidence, remission from UHR status, and the effects of transition to psychosis were evaluated. RESULTS: The number of participants in the CBTuhr group making the transition to psychosis increased from 10 at 18-month follow-up to 12 at 4-year follow-up whereas it did not change in the TAU group (n = 22); this still represents a clinically important (incidence rate ratio [IRR] = 12/22 = 0.55) and significant effect (F(1,5) = 8.09, P = .03), favoring CBTuhr. The odds ratio of CBTuhr compared to TAU was 0.44 (95% CI: 0.24-0.82) and the number needed to treat was 8. Moreover, significantly more patients remitted from their UHR status in the CBTuhr group (76.3%) compared with the TAU group (58.7%) [t(120) = 2.08, P = .04]. Importantly, transition to psychosis was associated with more severe psychopathology and social functioning at 4-year follow-up. CONCLUSIONS: CBTuhr to prevent a first episode of psychosis in persons at UHR of developing psychosis is still effective at 4-year follow-up. Our data also show that individuals meeting the formal criteria of a psychotic disorder have worse functional and social outcomes compared with non-transitioned cases. TRIAL REGISTRATION: The trial is registered at Current Controlled Trials as trial number ISRCTN21353122 (http://controlled-trials.com/ISRCTN21353122/gaag).
RCT Entities:
BACKGROUND: Previously, we demonstrated that cognitive behavior therapy for ultra-high risk (called CBTuhr) halved the incidence of psychosis over an 18-month period. Follow-up data from the same study are used to evaluate the longer-term effects at 4 years post-baseline. METHOD: The Dutch Early Detection and Intervention Evaluation study was a randomized controlled trial of 196 UHR patients comparing CBTuhr with treatment-as-usual (TAU) for comorbid disorders with TAU only. Of the original 196 patients, 113 consented to a 4-year follow-up (57.7%; CBTuhr = 56 vs TAU = 57). Over the study period, psychosis incidence, remission from UHR status, and the effects of transition to psychosis were evaluated. RESULTS: The number of participants in the CBTuhr group making the transition to psychosis increased from 10 at 18-month follow-up to 12 at 4-year follow-up whereas it did not change in the TAU group (n = 22); this still represents a clinically important (incidence rate ratio [IRR] = 12/22 = 0.55) and significant effect (F(1,5) = 8.09, P = .03), favoring CBTuhr. The odds ratio of CBTuhr compared to TAU was 0.44 (95% CI: 0.24-0.82) and the number needed to treat was 8. Moreover, significantly more patients remitted from their UHR status in the CBTuhr group (76.3%) compared with the TAU group (58.7%) [t(120) = 2.08, P = .04]. Importantly, transition to psychosis was associated with more severe psychopathology and social functioning at 4-year follow-up. CONCLUSIONS:CBTuhr to prevent a first episode of psychosis in persons at UHR of developing psychosis is still effective at 4-year follow-up. Our data also show that individuals meeting the formal criteria of a psychotic disorder have worse functional and social outcomes compared with non-transitioned cases. TRIAL REGISTRATION: The trial is registered at Current Controlled Trials as trial number ISRCTN21353122 (http://controlled-trials.com/ISRCTN21353122/gaag).
Authors: Alison R Yung; Hok Pan Yuen; Patrick D McGorry; Lisa J Phillips; Daniel Kelly; Margaret Dell'Olio; Shona M Francey; Elizabeth M Cosgrave; Eoin Killackey; Carrie Stanford; Katherine Godfrey; Joe Buckby Journal: Aust N Z J Psychiatry Date: 2005 Nov-Dec Impact factor: 5.744
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Judith Rietdijk; Sara Dragt; Rianne Klaassen; Helga Ising; Dorien Nieman; Lex Wunderink; Philippe Delespaul; Pim Cuijpers; Don Linszen; Mark van der Gaag Journal: Trials Date: 2010-03-22 Impact factor: 2.279
Authors: Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry Journal: Early Interv Psychiatry Date: 2017-07-18 Impact factor: 2.732
Authors: Brian O'Donoghue; Hellen Geros; Holly Sizer; Jean Addington; G Paul Amminger; Carrie E Beaden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Gregor Emanuel Berger; Eric Y H Chen; Lieuwe de Haan; Jessica A Hartmann; Ian B Hickie; Helga K Ising; Suzie Lavoie; Ashleigh Lin; Connie Markulev; Daniel H Mathalon; Thomas H McGlashan; Nathan G Mifsud; Nilufar Mossaheb; Dorien H Nieman; Merete Nordentoft; Diana O Perkins; Anita Riecher-Rössler; Miriam R Schäfer; Monika Schlögelhofer; Larry J Seidman; Stephan Smesny; Andrew Thompson; Ming T Tsuang; Mark van der Gaag; Swapna Verma; Elaine F Walker; Stephen J Wood; Scott W Woods; Hok Pan Yuen; Alison Ruth Yung; Patrick D McGorry; Barnaby Nelson Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2021-01-05 Impact factor: 4.328
Authors: David J Miklowitz; Jean M Addington; Mary P O'Brien; Danielle M Denenny; Marc J Weintraub; Jamie L Zinberg; Daniel H Mathalon; Barbara A Cornblatt; Michelle S Friedman-Yakoobian; William S Stone; Kristin S Cadenhead; Scott W Woods; Catherine A Sugar; Tyrone D Cannon; Carrie E Bearden Journal: Early Interv Psychiatry Date: 2021-08-23 Impact factor: 2.721
Authors: Inti Qurashi; Imran B Chaudhry; Ameer B Khoso; Sana Farooque; Steve Lane; Mohammad Omair Husain; Simon Chu; Jane Sarginson; Munir Hamarani; Haider A Naqvi; Bushra Razzaque; Fareed A Minhas; Alison R Yung; J F W Deakin; Nusrat Husain Journal: Trials Date: 2017-11-09 Impact factor: 2.279